AstraZeneca (NYSE: AZN) halts lung trial after survival goals seen unlikely
Rhea-AI Filing Summary
AstraZeneca PLC reported that it is discontinuing the Phase III eVOLVE-Lung02 trial of volrustomig plus chemotherapy as 1st-line treatment for metastatic non-small cell lung cancer with PD-L1 <50%. An Independent Data Monitoring Committee concluded the regimen was unlikely to meet the dual primary endpoints of progression-free survival and overall survival in patients with PD-L1 <1% compared with pembrolizumab plus chemotherapy. The safety profile was consistent with the known profiles of the individual medicines and no new safety signals were identified. AstraZeneca states that other Phase III volrustomig trials in cervical cancer, head and neck squamous cell carcinoma and mesothelioma continue as planned.
Positive
- None.
Negative
- AstraZeneca is discontinuing the Phase III eVOLVE-Lung02 trial after the monitoring committee found the volrustomig plus chemotherapy regimen was unlikely to meet the dual primary endpoints of progression-free survival and overall survival versus pembrolizumab plus chemotherapy in PD-L1 <1% metastatic NSCLC.
Key Figures
Patients enrolled: 895 patients
Volrustomig dose: 750mg
Pembrolizumab dose: 200mg
+4 more
7 metrics
Patients enrolled
895 patients
Patients enrolled in the eVOLVE-Lung02 Phase III trial across 25 countries
Volrustomig dose
750mg
Intravenous volrustomig plus chemotherapy every three weeks for four cycles, then volrustomig every three weeks
Pembrolizumab dose
200mg
Pembrolizumab plus chemotherapy every three weeks for four cycles, then pembrolizumab every three weeks
Treatment duration
24 months
Pembrolizumab regimen continued until completion of 24 months of treatment or disease progression or other discontinuation criterion
Cancer death share for lung cancer
23%
Lung cancer accounts for almost one in four (23%) cancer deaths globally
NSCLC share of lung cancer
80-85%
Non-small cell lung cancer accounts for 80-85% of lung cancer cases
5-year survival in metastatic NSCLC
12%
Approximately 12% of people with metastatic non-small cell lung cancer are alive five years after diagnosis
Key Terms
progression-free survival, overall survival, Independent Data Monitoring Committee, bispecific antibody, +1 more
5 terms
progression-free survival medical
"dual primary endpoints of progression-free survival (PFS) or overall survival (OS)"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
overall survival medical
"dual primary endpoints of progression-free survival (PFS) or overall survival (OS)"
Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.
Independent Data Monitoring Committee regulatory
"based on the recommendation of the Independent Data Monitoring Committee (IDMC)"
A panel of independent medical, statistical and ethical experts who review ongoing clinical trial data to judge participant safety, study integrity and whether the trial should continue, change or stop. Like impartial referees or safety inspectors, their decisions can speed, delay or halt a drug’s development and therefore materially affect a company’s timelines, regulatory chances and investment risk.
bispecific antibody medical
"Volrustomig is a dual checkpoint inhibitor bispecific antibody designed"
A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.
immuno-oncology medical
"AstraZeneca in immuno-oncology (IO) AstraZeneca is a pioneer"
Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.
FAQ
What did AstraZeneca (AZN) announce about the eVOLVE-Lung02 Phase III trial?
AstraZeneca announced it is discontinuing the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in 1st-line metastatic non-small cell lung cancer after an Independent Data Monitoring Committee said the regimen was unlikely to meet progression-free survival and overall survival endpoints versus pembrolizumab plus chemotherapy.
Why is AstraZeneca (AZN) stopping development in the eVOLVE-Lung02 lung cancer study?
The Independent Data Monitoring Committee concluded volrustomig plus chemotherapy was unlikely to meet the dual primary endpoints of progression-free survival and overall survival in PD-L1 <1% metastatic NSCLC, leading AstraZeneca to discontinue the eVOLVE-Lung02 trial while maintaining patient follow-up and care.
Does the eVOLVE-Lung02 decision affect other volrustomig trials at AstraZeneca (AZN)?
AstraZeneca states that only eVOLVE-Lung02 is being discontinued. Other Phase III volrustomig trials in cervical cancer, head and neck squamous cell carcinoma and mesothelioma continue as planned, indicating the broader programme for this bispecific antibody remains active.
Were any safety concerns reported for volrustomig in AstraZeneca’s (AZN) eVOLVE-Lung02 trial?
No new safety concerns were reported. AstraZeneca notes the safety profile of volrustomig plus chemotherapy was consistent with the known profiles of the individual medicines, and no new safety signals were identified during the Independent Data Monitoring Committee’s planned data review.
What patient population was targeted in AstraZeneca’s (AZN) eVOLVE-Lung02 Phase III trial?
The trial enrolled patients with metastatic non-small cell lung cancer whose tumours express PD-L1 <50%, with dual primary endpoints focused on progression-free and overall survival in the subgroup with PD-L1 <1%. It evaluated volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy as 1st-line therapy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
